London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Me too , hopefully it's yhe bottom this time but as I have said before the only bottom I can find is the one I scratch in a morning
Taken some more today it is just a matter of time before this reverses and catches a lot of people out. Get presentation deck out this week but clearly it is not for a retail audience. Which BP moves first?
Hi Energyshares Just a bit of light hearted tittle-tattle . Good CC supports her local team . Suspect she is still based in USA that seeems to be where the action is , & splits her time with regular commutes to UK to see the team . Important though the UK team can get on with science work .
Maybe why she started those Research & Development Spotlight series.
Anyway as long as it works for everyone should not matter (video conference would cut down air travel costs )
Ggmc
Interesting comment by CC ,and she knows her twitter account is stalked by Avacta SH’s for little clues.
Work meeting must be important that the CEO has to be there and not send a deputy over the weekend.
CC twitter account: She tweeted 8 hrs ago 3:30 am UK time.
“My @Phillies are officially in London. And I’m traveling elsewhere for work. All good. They’re gonna cream the @Mets”
Thanks for sharing alextak - more info
https://eprints.leedsbeckett.ac.uk/id/eprint/10927/7/AffimerReagentsAsToolMoleculesToModulatePlateletGpviligandInteractionsAndSpecificallyBindGpviDimerPV-HINDLE.pdf
"This work was supported by a joint Welcome Trust Investigator Award (204951/B/16/Z) to 460 SPW and RASA. RGX and RASA were further supported by the BBSRC (BB/W000237/1).
461 SPR and MST binding assays were performed in the Biomolecular Interactions facility, 462 Astbury Centre for Structural Molecular Biology, Faculty of Biological Sciences, University of 463 Leeds (part funded by the Wellcome Trust 062164/Z00/Z). SPW holds a BHF Chair (03/003).464 ANC acknowledges support of a Sir Henry Dale Fellowship jointly funded by the Wellcome 465 Trust and the Royal Society (Grant Number 220628/Z/20/Z), and the support of a University
466 Academic Fellowship from the University of Leeds. The RASA lab is further supported in part 467 by the National Institute for Health and Care Research (NIHR) Leeds Biomedical Research 468 Centre. The views expressed are those of the author(s) and not necessarily those of the 469 NHS, the NIHR or the Department of Health and Social Care. Funding from BBSRC
470 (BB/M012573/1) and the Wellcome Trust (208385/Z/17/Z) enabled the purchase of mass 471 spectrometry equipment."
Https://eprints.leedsbeckett.ac.uk/id/eprint/10927/
Not just Leeds:)
Rambo
Thanks I forgot Dr Tap ran the Lartruvo trial.
Lilly connection getting very interesting…
'What work does a biotech do prior to "preclinical" that would take that sort of time?' I think sometimes it's just a case of waiting in line. However, just because we haven't heard anything it doesn't mean fine tuning and tweeking isn't still taking place.
Energy - great post.
What we do know is that as part of that Point takeover Lilly would have performed due diligence on that business. There is zero doubt that the Precision license with them will have been part of that process. Lilly know exactly who Avacta are and well and truly in the mix here.
Just remember the Lartruvo trial that failed was a Lilly trial. Who ran that for them.....Dr TAP!
Sometime soon someone will break cover and the game will either be over or just beginning.
@JT I think you may well be right - LG certainly seem to be taking rheir time with affimers
point licensed from tufts originaly for a reason ?
What work does a biotech do prior to "preclinical" that would take that sort of time?
If AVA6000 moves to phase 2 (which it obviously will) and shows consistent efficacy that removes a massive risk for them in developing the radiotherapy version of pre|CISION.
I looked at the Point Bio pipeline in December or January after the EL TO, and Canseek was still in the Discovery phase. I think they were waiting for P1 readout before deciding whether to commit to the pre-clinical studies.
They state next step ongoing pre clinical that was in Nov 21
On pipeline they state discovery but Not disclosed.
Must be close to CTA and another milestone payment.
https://www.sec.gov/Archives/edgar/data/1811764/000181176421000017/pointbiopharmainvestorpr.htm
Well we don't know quite what stage POINT had got to and it will take a certain amount of time for Lilly to assess exactly what it is they've bought (technologies, pipeline, facilities, staff, etc.) and what they're going to use and what they're going to dispose of. Getting to the end of that by now I should imagine.
@ES - I don't think that Point had even started Pre-clinical work on Canseek before they were bought out. So, even if it was a priority for EL it wouldn't move into clinic for another year or two. My guess is, unfortunately, that EL's focus will be on the more advanced products in Point's pipeline, getting them through the clinic, for the time being. That said, in doing their due diligence for the TO, I'm sure their scientists looked in detail at all their assets, and perhaps Canseek stood out, so maybe they will start Preclinical work in the near future.
Agree BV but Point have had the licence for 3 years and Lilly 6 Months,Point stated they were waiting on Avacta results and have had a more insight into trial than anyone.
We should have had a CTA filing by now.
Correction : CC working
"
Christina Coughlin
@coughlin582
My
@Phillies
are officially in London. And I’m traveling elsewhere for work. All good. They’re gonna cream the
@Mets"
As we know, six months is not a lot of time in drug development. A licensing deal with Novartis for FAP-activated radiopharmaceutical prodrugs would certainly liven this sector up!
It’s this sort of company that will help make customised anti cancer vaccines quick to design and produce. It will blow chemotherapy out the water in a few years time. Thank heavens Precision has other applications.
Gje
Why ask me a question and when I answer in good faith you go back to being belligerent?
Also you make up stuff just to be argumentative. I didn’t say it was a crap share. Certainly I own enough to look into this BB twice a day to see if there is some good information. And sometimes there is, even once in a while from you.
So why are you such an angry belligerent person most of the time?
Maybe Lily are waiting to see how this trial goes …
https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.TPS3161
“PNT6555, a potent FAP-targeting compound with rapid clearance from normal tissues and prolonged tumor retention in preclinical models1, is a radioligand consisting of a DOTA chelator (1,4,7,10-tetraazacyclododecane-1,4,7,10- tetraacetic acid) and a FAP-targeting moiety (Bz-D-Ala-boroPro) connected via an aminomethyl linker.” Note that the PNT6555 molecule is out Tufts
Not a ‘million miles’ from pre|CISION™ then? Bearing in mind that ‘AVA6000 consists of a doxorubicin molecule covalently bonded to a dipeptide (pyridine-4-carbonyl)-D-Ala-L-Pro).’
But then we have ?
https://www.pharmaceutical-technology.com/data-insights/lutetium-lu-177-dotatate-point-biopharma-global-neuroendocrine-tumors-likelihood-of-approval/?utm_source=lgp5-loa&utm_medium=24-181531&utm_campaign=recommended-articles-pi
“POINT Biopharma Global overview”
“It utilizes CanSEEK platform technology to develop cancer treatments.”. So perhaps Lily still working on a CanSEEK based RLT?
All in a pay for report. How up-to-date, or accurate, who knows?
What is clear is that FAP targeting interest is significant in BP and we are at the ‘leading edge’ at least for Chemo, if not RLT.
GLA
Three and half years ago
Avacta granted their first licence to the Pre/Cision technology to Point Bio.
The agreement provides POINT with an exclusive license to the pre|CISION technology for use in the first radiopharmaceutical prodrug the company intends to develop, and a non-exclusive license to the pre|CISION™ platform for the development of a broader pipeline of FAP-activated radiopharmaceuticals.
That licence agreement now belongs to Eli Lilly.
Why after six months of owning this licence have they not submitted a CTA filing.
Are they keeping it under wraps while in talks.
They only have a non-exclusive license to the pre|CISION™ platform for the development of a broader pipeline of FAP-activated radiopharmaceuticals.
They only have one exclusive license to the pre|CISION technology for use in the first radiopharmaceutical prodrug.
So are they in talks for an exclusive licence for the broader pipeline to knock out the competition especially Novartis, or even a full T/O.
Handy : CC able to watch her team in London & Philadelphia
https://www.yahoo.com/news/philadelphia-phillies-way-london-mlb-124813315.html
https://x.com/coughlin582/status/1797805581052600751/photo/1
Baby reindeer springs to mind